Civil Plaintiff

Sun Pharma Agrees to $21M Settlement Over Acne Drug

A Sun Pharma unit on Aug. 24 agreed to pay $20.75 million to settle allegations of giving physicians misleading treatment instructions for its acne treatment Levulan Kerastick, causing insurers and federal healthcare programs to overpay for the drug, according to the U.S. Department of Justice.

Dusa Pharmaceuticals, which was acquired by Sun Pharma in 2012, allegedly told physicians Levulan Kerastick, an acne ointment applied along with an illuminated blue light, needed a one- to three-hour incubation period to be effective. However, clinical trials identified an effective incubation period to be within the 14- to 18-hour range.

Read the source article at Becker’s Hospital Review

    Leave a Review or Comment

    Your email address will not be published.

    Back to top button